漳州片仔癀药业股份有限公司 2025 年第三季度报告 漳州片仔癀药业股份有限公司2025 年第三季度报告 证券代码：600436 证券简称：片仔癀 一、主要财务数据 （一） 主要会计数据和财务指标 | | | | 单位：元 | 币种：人民币 | | --- | --- | --- | --- | --- | | | | 本报告期比 | | 年初至报告 | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 期末比上年 | | | | 减变动幅度 | | 同期增减变 | | | | (%) | | 动幅度(%) | | 营业收入 | 2,063,828,974.40 | -26.28 | 7,442,366,108.35 | -11.93 | | 利润总额 | 779,304,046.70 | -30.78 | 2,485,063,353.12 | -22.05 | | 归属于上市公司股东的净 | 687,038,367.44 | -28.82 | 2,129,347,677.38 | -20.74 | | 利润 | | | | | | 归属于上市公司股东的扣 | 437,772,369.72 | ...

Core Viewpoint - The company has initiated the Phase III clinical trial for its innovative traditional Chinese medicine, Wen Dan Pian, which aims to treat mild to moderate generalized anxiety disorder [1] Group 1: Clinical Development - The first subject has been enrolled in the Phase III clinical trial for Wen Dan Pian, which is designed to evaluate its efficacy and safety in treating generalized anxiety disorder [1] - The trial is a multicenter, randomized, double-blind, placebo-controlled study [1] - Wen Dan Pian is known for its effects in regulating qi, resolving phlegm, and calming the mind, and has been used clinically since 2007 as a hospital preparation [1]

片仔癀公告，第三季度营收为20.64亿元，同比下降26.28%；净利润为6.87亿元，同比下降28.82%。前 三季度营收为74.42亿元，同比下降11.93%；净利润为21.29亿元，同比下降20.74%。 ...

每经AI快讯，10月17日，片仔癀（600436）(600436.SH)公告称，公司研发的1.1类中药创新药温胆片已 完成Ⅲ期临床试验首例受试者入组，正式进入Ⅲ期临床试验。温胆片适应症为轻、中度广泛性焦虑障碍 (痰热内扰证)。 ...

新京报贝壳财经讯 10月17日，企查查APP显示，近日，广生合癀（漳州）医药有限公司成立，法定代 表人为黄晓航，注册资本为5000万元，经营范围包含：药品批发；第三类医疗器械经营；食品销售；保 健食品（预包装）销售；食品互联网销售（仅销售预包装食品）等。企查查股权穿透显示，该公司由广 生堂、片仔癀全资子公司福建片仔癀健康科技有限公司共同持股。 ...

Core Viewpoint - Guangsheng Hehuang (Zhangzhou) Pharmaceutical Co., Ltd. has been established with a registered capital of 50 million yuan, indicating a strategic move in the pharmaceutical and healthcare sector [1] Company Summary - The legal representative of the newly established company is Huang Xiaohang [1] - The company's business scope includes drug wholesale, third-class medical device operation, food sales, health food (pre-packaged) sales, and online sales of pre-packaged food [1] - The company is jointly owned by Guangsheng Tang and Fujian Pianzaihuang Health Technology Co., Ltd., a wholly-owned subsidiary of Pianzaihuang [1]

Core Viewpoint - Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. announced its participation in the CICC Medical Fund, focusing on investments in the healthcare sector, particularly in traditional Chinese medicine, biomedicine, medical devices, and related industries [1] Group 1 - The CICC Medical Fund aims to raise a total of 1 billion RMB, with Zhangzhou Pien Tze Huang Investment Management Co., Ltd. committing to invest 200 million RMB, representing 20% of the fund's target size [1] - The fund will primarily invest in projects related to the Pien Tze Huang industry chain, Pien Tze Huang industrial park, and other projects that attract investment to Zhangzhou [1] - The investment strategy aligns with the growing trend in the healthcare sector, emphasizing the importance of traditional Chinese medicine and related health services [1]

Core Insights - A new company, Guangsheng Hehuang (Zhangzhou) Pharmaceutical Co., Ltd., has been established with a registered capital of 50 million yuan [1] - The company's business scope includes drug wholesale, food sales, health food sales, and online food sales [1] - The ownership structure shows that Guangsheng Tang holds 51% and Fujian Pianzaihuang Health Technology Co., Ltd. holds 49% [1]

Core Viewpoint - Recently, a new investment partnership named Zhongjin (Zhangzhou) Medical Industry Investment Partnership (Limited Partnership) was established with a capital of 1 billion yuan, focusing on investment activities using its own funds [1] Group 1: Company Information - The new partnership is co-funded by Pianzaihuang's wholly-owned subsidiary Zhangzhou Pianzaihuang Investment Management Co., Ltd. and Zhongjin Company's wholly-owned subsidiary Zhongjin Capital Operation Co., Ltd. [1]

Core Insights - The Medical Health Index (980016) closed at 6759.45 points, up 1.78%, with a trading volume of 27.946 billion yuan and a turnover rate of 1.0% [1] - Among the index constituents, 40 stocks rose, with Huahai Pharmaceutical leading at a 7.59% increase, while 9 stocks fell, with BGI Genomics leading the decline at 2.93% [1] Index Performance - The Medical Health Index saw a net inflow of 1.063 billion yuan from main funds, while retail investors experienced a net outflow of 392 million yuan [1] - The top ten constituents of the index include major companies such as WuXi AppTec, Hengrui Medicine, and Mindray Medical, with varying market capitalizations and price changes [1] Fund Flow Analysis - Huahai Pharmaceutical had a main fund net inflow of 163 million yuan, while retail investors saw a net outflow of 76.6 million yuan [2] - Other notable companies with significant fund flows include Aier Eye Hospital and Hengrui Medicine, both experiencing mixed inflows and outflows from different investor categories [2]